Hospital
Memorial Hospital Flagler INC
Memorial Hospital Flagler INC was paid $13.86M by Medicaid between Jan 2018 and Dec 2024, across 180 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL FLAGLER INC
PALM COAST, FL 32164
PALM COAST, FL 32164
33aNPI1679678486assigned 09/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.86M
24GClaims299,214
24DCodes billed180
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#33 of 163
Median peer was paid$4.77M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,961 | $438K | |
| 2019 | 61,647 | $3.11M | |
| 2020 | 49,573 | $2.43M | |
| 2021 | 66,559 | $3.10M | |
| 2022 | 69,196 | $2.92M | |
| 2023 | 28,039 | $1.53M | |
| 2024incomplete | 4,239 | $331K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 17,912 | 16,541 | $2.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 14,842 | 13,021 | $1.55M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.7% | 11,209 | 2,744 | $1.34M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 8.2% | 6,558 | 1,320 | $1.13M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.2% | 4,208 | 3,591 | $717K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 6,577 | 5,670 | $614K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.7% | 3,618 | 3,176 | $512K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 2,119 | 1,916 | $479K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.0% | 5,420 | 1,437 | $415K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 2,903 | 2,496 | $396K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 1,726 | 1,489 | $358K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 2,648 | 2,501 | $298K |
168 more codes
| 80053 | Comprehensive metabolic panel | 2.1% | 16,355 | $286K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 1,116 | $252K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 3,309 | $200K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 4,079 | $189K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 1,745 | $167K |
| 81025 | 1.0% | 3,753 | $141K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,311 | $131K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,991 | $125K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,156 | $97K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,926 | $93K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,771 | $84K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,263 | $83K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,284 | $82K |
| 81001 | <1% | 9,777 | $72K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,328 | $72K |
| 82947 | <1% | 3,511 | $71K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,437 | $70K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,434 | $62K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,082 | $59K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,335 | $58K |
| 87631 | <1% | 326 | $57K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 234 | $57K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,636 | $56K |
| 84484 | <1% | 5,818 | $55K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,594 | $54K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 471 | $49K |
| G0378 | Hospital observation service, per hour | <1% | 2,251 | $46K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,590 | $46K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 521 | $43K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,466 | $43K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 446 | $42K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 304 | $41K |
| 87807 | <1% | 234 | $37K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,097 | $36K |
| 74018 | <1% | 744 | $35K | |
| 97161 | <1% | 160 | $34K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,514 | $33K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 530 | $33K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,810 | $32K |
| 73630 | <1% | 552 | $29K | |
| 73610 | <1% | 467 | $29K | |
| 86901 | <1% | 810 | $28K | |
| 81003 | <1% | 2,463 | $27K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,966 | $27K |
| 85610 | <1% | 5,277 | $27K | |
| 83605 | <1% | 3,038 | $27K | |
| 97162 | <1% | 153 | $23K | |
| 01999 | <1% | 1,307 | $22K | |
| 83690 | <1% | 4,262 | $22K | |
| 96376 | <1% | 1,301 | $21K | |
| 80050 | General health panel | <1% | 576 | $20K |
| 85730 | <1% | 3,968 | $20K | |
| 87186 | <1% | 1,377 | $19K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 901 | $19K |
| 80061 | Lipid panel | <1% | 4,472 | $19K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 707 | $18K |
| 73130 | <1% | 382 | $17K | |
| 73564 | <1% | 513 | $17K | |
| 87040 | <1% | 2,438 | $16K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 140 | $16K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,872 | $15K |
| 83735 | <1% | 2,960 | $14K | |
| 72100 | <1% | 308 | $14K | |
| 92523 | <1% | 63 | $12K | |
| 84702 | <1% | 837 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 202 | $12K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,970 | $11K |
| J2704 | Injection, propofol, 10 mg | <1% | 639 | $10K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 44 | $10K |
| 73030 | <1% | 404 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 370 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,693 | $10K |
| 83516 | <1% | 70 | $9K | |
| 84703 | <1% | 1,820 | $9K | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 528 | $9K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 31 | $8K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 121 | $8K |
| 73110 | <1% | 201 | $8K | |
| 87077 | <1% | 1,554 | $7K | |
| 76377 | <1% | 243 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 61 | $6K |
| 83880 | <1% | 1,409 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,446 | $6K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 124 | $5K |
| 72131 | <1% | 37 | $5K | |
| 93971 | <1% | 222 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 440 | $4K |
| 86900 | <1% | 813 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 510 | $4K |
| 87634 | <1% | 72 | $4K | |
| 86850 | <1% | 200 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,095 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,345 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,061 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 245 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 497 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 104 | $3K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 127 | $2K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 635 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 12 | $2K |
| 97166 | <1% | 15 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 217 | $2K |
| 85379 | <1% | 647 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 332 | $1K |
| 85027 | <1% | 572 | $1K | |
| 76801 | <1% | 157 | $1K | |
| 82607 | <1% | 1,257 | $1K | |
| 82728 | <1% | 530 | $1K | |
| 80076 | <1% | 208 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 159 | $1K |
| 73140 | <1% | 42 | $1K | |
| 84481 | <1% | 114 | $973.93 | |
| 84100 | <1% | 172 | $970.46 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14 | $948.76 |
| 93017 | <1% | 14 | $813.29 | |
| 86140 | <1% | 336 | $806.13 | |
| 84439 | <1% | 1,549 | $746.31 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 59 | $722.29 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 104 | $673.12 |
| 76830 | Ultrasound, transvaginal | <1% | 43 | $659.57 |
| 82746 | <1% | 393 | $582.74 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 14 | $576.58 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 14 | $576.58 |
| 94760 | <1% | 134 | $573.75 | |
| 80069 | <1% | 18 | $569.52 | |
| 84155 | <1% | 88 | $538.31 | |
| 82247 | <1% | 99 | $521.24 | |
| 84460 | <1% | 98 | $516.14 | |
| 82040 | <1% | 85 | $516.14 | |
| 84075 | <1% | 84 | $516.14 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 810 | $495.85 |
| 97116 | <1% | 40 | $443.34 | |
| 83540 | <1% | 641 | $404.51 | |
| 82077 | <1% | 332 | $342.87 | |
| 85652 | <1% | 501 | $304.47 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 191 | $297.17 |
| 84550 | <1% | 100 | $221.88 | |
| 84466 | <1% | 411 | $197.89 | |
| 82565 | <1% | 111 | $176.60 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 29 | $173.08 |
| 82550 | <1% | 90 | $158.84 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 109 | $150.66 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 77 | $121.82 |
| 82043 | <1% | 138 | $107.48 | |
| 83550 | <1% | 55 | $86.80 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 31 | $65.95 |
| 82570 | <1% | 316 | $65.30 | |
| 84480 | <1% | 14 | $59.87 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 32 | $43.86 |
| 90715 | <1% | 77 | $43.57 | |
| 84436 | <1% | 31 | $24.19 | |
| 86038 | <1% | 13 | $23.39 | |
| 82248 | <1% | 115 | $21.54 | |
| 87070 | <1% | 14 | $8.35 | |
| 85018 | <1% | 19 | $5.64 | |
| 87210 | 0% | 13 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 90 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 32 | $0.00 |
| 83525 | 0% | 29 | $0.00 | |
| 85007 | 0% | 47 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 19 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 66 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 12 | $0.00 |
| 87486 | 0% | 32 | $0.00 | |
| 83527 | 0% | 26 | $0.00 | |
| 94762 | 0% | 48 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRATHBUN, MARK (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Memorial Hospital Flagler INC. | Palm Coast, FL | $2.11M |
| Adventhealth Palm Coast Parkway INC | Palm Coast, FL | $401K |
| Southeast Volusia Healthcare Corporation | New Smyrna Beach, FL | $41K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.